TELA Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TELA research report →
Range $2 – $2
Price Chart
About the company
TELA Bio, Inc. , a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
- CEO
- Heather Getz
- IPO
- 2019
- Employees
- 218
- HQ
- Malvern, PA, US
Get TickerSpark's AI analysis on TELA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $31.11M
- P/E
- -0.98
- PEG
- -0.05
- P/S
- 0.42
- P/B
- -1.71
- EV/EBITDA
- -2.02
- Div Yield
- 0.00%
- Gross Margin
- 67.19%
- Op Margin
- -43.17%
- Net Margin
- -53.57%
- ROE
- 425.91%
- ROIC
- -102.46%
Latest fiscal year · YoY change
- Revenue
- $80.28M+15.8%
- Gross Profit
- $54.34M+16.9%
- Op Income
- $-33,755,000
- Net Income
- $-38,831,000-2.6%
- EPS
- $-0.83+37.6%
- OCF Growth
- +32.2%
- FCF Growth
- +32.7%
- 52W High
- $1.50
- 52W Low
- $0.50
- 50D MA
- $1.02
- 200D MA
- $0.85
- Beta
- 1.46
- RSI (14)
- 35
- Avg Volume
- 217.44K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
TELA Bio said Q3 revenue fell 8% year over year, but cost cuts, better U.S. hernia execution, and European growth improved cash burn and set up a sequentially stronger Q4.· November 10, 2026
- Q3 revenue was $19 million, down 8% year over year, with U.S. revenue of $15.4 million and Europe at $3.6 million.
- Adjusted EBITDA loss improved to $3.4 million, a 40% year-over-year improvement and 56% sequential improvement.
- Gross margin was 64.9%, or 71% excluding a $1.1 million noncash excess-and-obsolete inventory charge.
- Management said the $17 million cost reduction plan is substantially complete and should lower 2027 expenses to $76 million-$78 million.
- Leadership expects sequential growth in Q4 and continued growth into 2027, but said the turnaround is multi-quarter, not a one-quarter fix.
TELA Bio reported third-quarter 2026 revenue of $19 million, down 8% from Q3 2025. Gross profit was $12.3 million, or 64.9% of revenue, versus $14 million, or 67.5%, a year ago; excluding a $1.1 million noncash excess-and-obsolete inventory charge, gross margin would have been 71%. Operating expenses, excluding other expenses, were $17.6 million, down 17.8% year over year, and loss from operations was $7.3 million, a $300,000 improvement year over year. Adjusted EBITDA loss was $3.4 million, improving 40% year over year and 56% sequentially. The company ended the quarter with $22.7 million in cash and cash equivalents. For the business outlook, management expects sequential growth in Q4, continued growth into 2027, and said 2027 expenses should be in the $76 million to $78 million range after the $17 million cost reduction program.
Heather Getz framed the quarter as an early stage of a broader reset focused on stabilizing the company, extending runway, and sharpening commercial priorities. She said the business has a substantial market opportunity, citing a roughly $4 billion worldwide TAM and $3 billion U.S. TAM, and believes the changes already made can help TELA Bio return to double-digit growth over time. Her tone was constructive but measured: she emphasized that Q4 should improve sequentially, but that the turnaround will take multiple quarters and is not yet complete.
Heather Getz said the $17 million annualized cost reduction plan started September 1 and is now substantially complete, with a targeted headcount reduction of about 20% and lower external spend. She highlighted that even with only a partial quarter of savings, adjusted EBITDA loss improved to $3.4 million, and she expects 2027 expenses to land in the $76 million to $78 million range. She also noted $22.7 million in cash and cash equivalents at quarter-end and said Perceptive agreed to suspend minimum revenue covenant testing for two quarters, specifically the periods ending September 30 and December 31, 2026.
Analysts pressed management on the longer-term growth profile, and Heather said TELA still believes it can accelerate back into double-digit growth, though the timing is still being evaluated. Multiple questions focused on PRS, where management said the dedicated-rep experiment has been rolled back and the team is now refocused on selling the whole portfolio, rebuilding the funnel, and supporting existing users. They also asked about Q4 and 2027, and management said it expects sequential growth in Q4 and continued growth into 2027, with U.S. hernia and LIQUIFIX showing better momentum after the realignment.
The call showed improving commercial execution after the reorganization, including sequential U.S. hernia growth, a record quarter for LIQUIFIX, and continued double-digit growth in Europe. Management also pointed to stronger clinical evidence for OviTex and PRS, plus the FDA 510(k) clearance for Liora, as support for the portfolio and future commercial options. The lower cost structure should reduce cash burn and improve the path to a more durable business model.
PRS remains a weak spot, with revenue down 20% year over year and 6% sequentially, and management said the recovery will take time because the market has a longer sales cycle and some accounts were lost to physician turnover. Heather also cited hospital bundling and contracting barriers from larger competitors, which limit access in some accounts. The company ended with $22.7 million in cash and needed covenant relief from Perceptive, underscoring that liquidity and execution remain important risks.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 74.0%
- Shares Outstanding
- 45.19M
- Float Shares
- 33.45M
of shares held by institutions
44 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Essex Woodlands Management, Inc. | 7.71M | 0 |
| Nantahala Capital Management, LLC | 6.55M | ▲ 651.48K |
| Silverarc Capital Management, LLC | 2.14M | 0 |
| Perkins Capital Management Inc | 2.08M | ▲ 707.35K |
| Vanguard Group Inc | 1.83M | ▲ 30.67K |
| Vanguard Capital Management LLC | 1.57M | 0 |
| Dafna Capital Management LLC | 1.44M | 0 |
| Up Strategic Wealth Investment Advisors LLC | 641.56K | ▲ 541.67K |
| Sio Capital Management, LLC | 636.30K | 0 |
| Wealthtrust Axiom LLC | 550.13K | ▲ 92.39K |
| Geode Capital Management, LLC | 412.66K | ▲ 23.44K |
| White Pine Capital LLC | 405.66K | ▲ 405.66K |
Held by 25 ETFs
Biggest fund positions in TELA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 15, 26 | Capper Joseph H | other | 19,801 |
| Oct 15, 26 | Plovanic William J. | other | 16,089 |
| Sep 17, 26 | Capper Joseph H | buy | 25,000 |
| Sep 16, 26 | Capper Joseph H | buy | 50,000 |
| Sep 15, 26 | Capper Joseph H | buy | 50,000 |
| Sep 14, 26 | Capper Joseph H | buy | 25,000 |
| Aug 17, 26 | Getz Heather C | buy | 12,500 |
| Aug 14, 26 | Getz Heather C | buy | 15,000 |
| Aug 3, 26 | Getz Heather C | other | 1,365,000 |
| Aug 3, 26 | Getz Heather C | other | 1,005,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TELA coverage
Recent articles, reports, and earnings notes.
No research on TELA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TELA report →TELA Bio, Inc. (TELA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
TELA Bio, Inc. (TELA) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 10
TELA Bio Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 10
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 6
TELA Bio to Announce Third Quarter 2026 Financial Results
globenewswire.com · Oct 27
TELA Bio, Inc. (TELA) Shareholder/Analyst Call Transcript
seekingalpha.com · Oct 8
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
globenewswire.com · Oct 5
Insider Buying: TELA Bio (NASDAQ:TELA) Director Acquires $30,500.00 in Stock
defenseworld.net · Sep 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.